Winning Combination loses NAD challenge
This article was originally published in The Tan Sheet
Executive Summary
The Winning Combination should discontinue claims that its Resolve smoking cessation aid is "clinically proven" to help smokers quit "once and for all" with "less stress and anxiety," the National Advertising Division says Oct. 28. NAD advises the advertiser to discontinue broad efficacy claims and some testimonials. The Winnipeg, Manitoba-based firm claims Resolve has natural ingredients and that the key ingredient ethyl maltol reduces cigarette consumption. The Winning Combination disagrees with NAD, but "will accede to the requests." GlaxoSmithKline, which sells Nicorette, Commit and NicoDerm CQ OTC NRT products, brought the challenge. In August 2008, Health Canada stated Resolve remains unauthorized for use there following a June 2007 advisory and recall the agency issued concerning the ingredient Cestemenol-350. The agency said in excessive amounts, Cestemenol-350 may cause damage to the kidney, liver or red blood cells (1"The Tan Sheet" Aug. 6, 2007, In Brief)
The Winning Combination should discontinue claims that its Resolve smoking cessation aid is "clinically proven" to help smokers quit "once and for all" with "less stress and anxiety," the National Advertising Division says Oct. 28. NAD advises the advertiser to discontinue broad efficacy claims and some testimonials. The Winnipeg, Manitoba-based firm claims Resolve has natural ingredients and that the key ingredient ethyl maltol reduces cigarette consumption. The Winning Combination disagrees with NAD, but "will accede to the requests." GlaxoSmithKline, which sells Nicorette , Commit and NicoDerm CQ OTC NRT products, brought the challenge. In August 2008, Health Canada stated Resolve remains unauthorized for use there following a June 2007 advisory and recall the agency issued concerning the ingredient Cestemenol-350. The agency said in excessive amounts, Cestemenol-350 may cause damage to the kidney, liver or red blood cells (1 'The Tan Sheet' Aug. 6, 2007, In Brief). |